pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute for clinical programs — 83 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
George Institute for projects
83 ClinicalTrials.gov programs sponsored by George Institute for.
George Institute for has 83 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Metformin Actavis 500 mg filmdragerad tablett
The George Institute
Polycystic ovary syndrome
1 trial -
Mounjaro solution for injection in pre-filled... for Obesity
The George Institute
Obesity
1 trial -
NORD-STAR
The George Institute
Rheumatoid Arthritis
1 trial -
Norfloxacino Sandoz 400 mg comprimidos EFG
The George Institute
Hospitalized patients with decompensated cirrhosis, diagnosed with bacterial infection evolution lasting for 48 hours or less.
1 trial -
OHIRC-20150866
The George Institute
Risk of stroke by Atrial Fibrillation
1 trial -
OralAntiseptic_Virus
The George Institute
Respiratory diseases
1 trial -
PI21/004444
The George Institute
Latent tuberculosis infection in patients with end-stage kidney disease.
1 trial -
PI24/01356
The George Institute
Type 2 diabetes
1 trial -
PREDICT study
The George Institute
Cardiovascular device infections
1 trial -
Pentocur pulver till injektionsvätska for Major depressive disorder
The George Institute
Major depressive disorder
1 trial -
Plasma rich in growth factors, -
The George Institute
Glaucoma, Dry eye disease
1 trial -
Prednisona Pensa comprimidos EFG for Kidney Transplant
The George Institute
Kidney Transplant
1 trial -
Providence
The George Institute
Cervical cancer
1 trial -
RC-P0055
The George Institute
Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.
1 trial -
RC-P0103
The George Institute
lumbosacral radiculalgia
1 trial -
RIBOCICLIB, Kisqali 200 mg film-coated tablets
The George Institute
Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence
1 trial -
ROPIDOL
The George Institute
lumbar arthrodesis
1 trial -
ROSUVASTATIN for CHRONIC INFLAMMATORY RHEUMATIC…
The George Institute
CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoriatic arthritis or axial spondyloarthritis or systemic lupus erythematosus
1 trial -
Rabipur Pulver und Lösungsmittel zur Herstell...
The George Institute
rabies pre-exposure prophylaxis
1 trial -
Renoir
The George Institute
Covid-19 infection
1 trial -
SAFE-BK
The George Institute
BK Polyomavirus DNAemia after kidney transplantation
1 trial -
SEDA
The George Institute
Patients with major depressive episode and moderate to severe insomnia disorder
1 trial -
SILDENAFIL , LEVOTHYROXINE SODIUM
The George Institute
erectile function, hypothyroidism subclinic
1 trial -
SIMA SPK 01
The George Institute
End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA
1 trial -
SINECATECHINS
The George Institute
Anal high-grade squamous intraepithelial lesions (HSIL).
1 trial -
TESTOGEL for low ovarian reserve according t…
The George Institute
low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism
1 trial -
TRANEXAMIC ACID
The George Institute
Hip fracture
1 trial -
TRAPEZIUS
The George Institute
TRAPEZIUS MYOFASCIAL SYNDROME IN FIBROMYALGIA PATIENTS
1 trial -
TailorDose-II
The George Institute
Breast cancer female NOS
1 trial -
Trangorex 200 mg comprimidos
The George Institute
Atrial fibrillation
1 trial -
Ultomiris 300 mg/30 mL concentrate for solution for infusion
The George Institute
IgA nephropathy
1 trial -
Vabysmo 120 mg/mL solution for injection in pre-filled syringe
The George Institute
SUBRETINAL HYPERREFLECTIVE MATERIAL
1 trial -
Vyvgart 20 mg/mL concentrate for solution for infusion
The George Institute
Patients affected by generalized myasthenia gravis
1 trial -
Wegovy 2.4 mg solution for injection in pre-filled pen
The George Institute
obstructive sleep apnea
1 trial -
Xtandi - 40 mg soft capsules
The George Institute
PROSTATE CANCER
1 trial
Frequently asked questions
How many clinical projects does George Institute for have?
83 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.